GB2303853A - Defects in drug metabolism - Google Patents

Defects in drug metabolism

Info

Publication number
GB2303853A
GB2303853A GB9626479A GB9626479A GB2303853A GB 2303853 A GB2303853 A GB 2303853A GB 9626479 A GB9626479 A GB 9626479A GB 9626479 A GB9626479 A GB 9626479A GB 2303853 A GB2303853 A GB 2303853A
Authority
GB
United Kingdom
Prior art keywords
drug metabolism
defects
cyp2a6
mutations
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9626479A
Other versions
GB2303853B (en
GB9626479D0 (en
Inventor
Frank J Gonzalez
Jeffrey R Idle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412054A external-priority patent/GB9412054D0/en
Priority claimed from GBGB9502728.0A external-priority patent/GB9502728D0/en
Priority claimed from GBGB9507640.2A external-priority patent/GB9507640D0/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of GB9626479D0 publication Critical patent/GB9626479D0/en
Publication of GB2303853A publication Critical patent/GB2303853A/en
Application granted granted Critical
Publication of GB2303853B publication Critical patent/GB2303853B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to genetic material, and specifically portions of DNA, for identifying the presence or absence of a mutation in the drug metabolism gene CYP2C9 and CYP2A6. Further, the invention comprises a method for determining such mutations and a kit incorporating the genetic material of the invention for performing the said methods so as to determine the presence or absence of mutations in the drug metabolizing gene CYP2C9 and CYP2A6.
GB9626479A 1994-06-16 1995-06-16 Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes Expired - Fee Related GB2303853B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9412054A GB9412054D0 (en) 1994-06-16 1994-06-16 Defects in drug metabolism
GBGB9502728.0A GB9502728D0 (en) 1994-06-16 1995-02-13 Defects in drug metabolism
GBGB9507640.2A GB9507640D0 (en) 1995-04-12 1995-04-12 Defects in drug metabolism
PCT/US1995/007605 WO1995034679A2 (en) 1994-06-16 1995-06-16 Defects in drug metabolism

Publications (3)

Publication Number Publication Date
GB9626479D0 GB9626479D0 (en) 1997-02-05
GB2303853A true GB2303853A (en) 1997-03-05
GB2303853B GB2303853B (en) 1998-12-23

Family

ID=27267237

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9626479A Expired - Fee Related GB2303853B (en) 1994-06-16 1995-06-16 Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes

Country Status (3)

Country Link
AU (1) AU2860295A (en)
GB (1) GB2303853B (en)
WO (1) WO1995034679A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422205D0 (en) * 1994-11-03 1994-12-21 British Gas Plc Enzyme mutant and method
SK55598A3 (en) * 1995-11-01 1999-04-13 British Gas Plc Mutant mono-oxygenase cytochrome p450cam
PL326445A1 (en) * 1995-11-01 1998-09-28 British Gas Plc Mutant of cytochrome p450cam mono-oxygenase
CA2227423A1 (en) * 1996-07-17 1998-01-29 Edward M. Sellers Methods for regulating nicotine metabolism
WO1999027919A2 (en) * 1997-07-17 1999-06-10 Nicogen Inc. Cyp2a enzymes and their use in therapeutic and diagnostic methods
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6605430B1 (en) 1998-08-12 2003-08-12 Maxygen, Inc. DNA shuffling of monooxygenase genes for production of industrial chemicals
EP1108065A1 (en) * 1998-08-28 2001-06-20 Sangtec Molecular Diagnostics AB A method for measuring a patient's ability to metabolise certain drugs
AU3064800A (en) * 1999-01-21 2000-08-07 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
WO2000066775A1 (en) * 1999-04-28 2000-11-09 Sumitomo Pharmaceuticals Company, Limited Cyp2a6 gene judgment methods
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
US20040084867A1 (en) * 2002-06-28 2004-05-06 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
EP1670947B1 (en) 2003-09-23 2015-04-01 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
AU2005295546B2 (en) * 2004-10-18 2011-11-10 University Of Washington Methods and compositions for predicting drug responses
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
JP2008532544A (en) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
CN113215121B (en) * 2021-06-07 2021-12-17 云南师范大学 Method for efficiently and heterogeneously synthesizing mogroside V precursor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody
WO1994001548A2 (en) * 1992-07-13 1994-01-20 Medical Research Council Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody
WO1994001548A2 (en) * 1992-07-13 1994-01-20 Medical Research Council Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Amer.J.Human Genetics 1995,57,651-660 *
Biochemistry 1990,29,1322-1329 *
Carcinogenesis 1993,14(7),1421-1427 *

Also Published As

Publication number Publication date
AU2860295A (en) 1996-01-05
GB2303853B (en) 1998-12-23
GB9626479D0 (en) 1997-02-05
WO1995034679A3 (en) 1996-03-21
WO1995034679A2 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
GB2303853A (en) Defects in drug metabolism
IL91501A0 (en) Binding protein
NZ284412A (en) Apolipoprotein E polymorphism and treatment of Alzheimer's Disease
ZA99133B (en) Transgenic rabbit that expresses a functional human lipoprotein (A).
WO1998030883A3 (en) Analysis of genetic polymorphisms and gene copy number
WO2001029257A3 (en) Methods of genetic cluster analysis
DE69838510D1 (en) MUTATIONS IN ATP-DEPENDENT TRANSPOSITION PROTEINS THAT REDUCE THE DESTINATION SPECIFICITY
EP1036844A4 (en) Examination method, examination reagent and remedy for diseases caused by variation in lkb1 gene
AU3822199A (en) Basb013 dna and proteins from neisseria meningitidis
AU2687397A (en) Method and reagents for testing for mutations in the brca1 gene
AU6252796A (en) Nucleic acid repair enzyme methods for point mutation detect ion and in vitro mutagenesis
van Meijer et al. Selective Screening of a Large Phage Display Library of Plasminogen Activator Inhibitor 1 Mutants to Localize Interaction Sites with Either Thrombin or the Variable Region 1 of Tissue-type Plasminogen Activator (∗)
IL124791A0 (en) Constructs and methods for enhancing protein levels in photosynthetic organisms
DE69716057D1 (en) METHOD AND COMPOSITIONS FOR DETECTING SPLICE MUTATIONS IN DIHYDROPYREMUDINE DEHYDROGENASE
ATE257515T1 (en) GENES FOR BUTYROBETAIN/CROTONOBETAIN-L-CARNITINE METABOLISM AND THEIR USE FOR MICROBIOLOGICAL PRODUCTION OF L-CARNITINE
EP0857780A4 (en) Novel proteins remarkably expressed in liver cancer, genes encoding the same, antibodies against the same, and method for detecting the expression of the same
WO1997035878A3 (en) The porcine heart fatty acid-binding protein encoding gene and methods to identify polymorphisms associated with body weight
MX9600860A (en) Method of detecting human cytochrome p4501a2 gene polymorphism.
GB0104647D0 (en) Method for the identification and speciation of bacteria of the burkholderia cepacia complex
ATE366322T1 (en) NEW ENZYMES AND METABOLITES IN SKATOL METABOLISM
EP1016717A4 (en) Novel protein remarkably expressed in hepatic cancer, gene encoding the same, antibody thereto, and method for detecting the expression thereof
AU6278099A (en) Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide
AU2905497A (en) Methods for identifying a mutation in a gene of interest
AU2001273842A1 (en) Method for identifying and isolating genome fragments with linkage disequilibrium
Rahman et al. Physical map location of the peptide methionine sulfoxide reductase gene on the Escherichia coli chromosome

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20140616